勒梅特微管医疗 2026年季度报告

FORM 10-Q (Mark One)☒QUARTERLY REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended March 31, 2026Or☐TRANSITION REPORT PURSUANT TO SECTION13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period fromto.Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware04-2825458(State or other jurisdiction ofincorporation or organization)(I.R.S. EmployerIdentification No.)63 Second Avenue, Burlington, Massachusetts01803(Address of principal executive offices)(Zip Code)(781) 221-2266(Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Exchange Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days. Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company” and “emerging growth company “in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒As of May 4, 2026, the registrant had 22,850,739 shares of common stock, par value $.01 per share, outstanding. LEMAITRE VASCULARFORM 10-QTABLE OF CONTENTS Part I.Financial Information: Item 1.Financial Statements1Consolidated Balance Sheets as of March 31, 2026 (unaudited) and December 31, 20251Unaudited Consolidated Statements of Operations for the three-month periods ended March 31, 2026 and20252Unaudited Consolidated Statements of Comprehensive Income for the three-month periods ended March31, 2026 and 20253Unaudited Consolidated Statements of Stockholders’ Equity for the three-month periods ended March 31,2026 and 20254Unaudited Consolidated Statements of Cash Flows for the three-month periods ended March 31, 2026 and20255Notes to Unaudited Consolidated Financial Statements6Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations17Item 3.Quantitative and Qualitative Disclosure about Market Risk25Item 4.Controls and Procedures25Part II. Other Information:27Item 1.Legal Proceedings27Item 1A. Risk Factors27Item 2.Unregistered Sales of Equity Securities and Use of Proceeds27Item 5.Other Information27Item 6.Exhibits28Signatures29 LeMaitre Vascular, Inc. Consolidated Statements of Operations(unaudited) Three months endedMarch 31, LeMaitre Vascular, Inc. Consolidated Statements of Comprehensive Income(unaudited) Three months endedMarch 31,20262025(in thousands)Net income$15,679$11,011Other comprehensive income (loss):Foreign currency translation adjustment, net(559)828Unrealized (loss) gain on marketable securities(887)203Total other comprehensive (loss) income(1,446)1,031Comprehensive income$14,233$12,042 LeMaitre Vascular, Inc. LeMaitre Vascular, Inc. Consolidated Statements of Cash Flows(unaudited) Investing activities Financing activities LeMaitre Vascular, Inc. Notes to Consolidated Financial StatementsMarch 31, 2026(unaudited) 1. Basis of Presentation and Summary of Significant Accounting Policies Overview Unless the context requires otherwise, references to LeMaitre, LeMaitre Vascular, and the Company refer to LeMaitreVascular, Inc. and its subsidiaries. The Company’s consolidated financial statements have been prepared in conformity withaccounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicableguidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (“ASC”) and AccountingStandards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). The accompanying unaudited consolidatedfinancial statements have been prepared on the basis of continuity of operations, realization of assets and the satisfaction ofliabilities and commitments in the ordinary course of business. The consolidated financial statements include the accounts of theCompany and its